Recro Pharma, Inc. (NASDAQ:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for post-operative pain, today announced the appointments of Alfred F. Altomari and Dr. Michael Berelowitz to the Company’s Board of Directors. Recro Pharma Inc (NASDAQ:REPH) stock performance was 1.95% in last session and finished the day at $7.32. Traded volume was 35,553.00million shares in the last session and the average volume of the stock remained 141.13K shares. Recro Pharma Inc (NASDAQ:REPH) insider ownership is 45.70%.

Sophiris Bio Inc. (NASDAQ:SPHS), a biopharmaceutical company developing a clinical stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the 13th Annual Needham Healthcare Conference. Sophiris Bio Inc (NASDAQ:SPHS) rose 1.83 percent to $3.33 Monday on volume of 47,957.00million shares. The intra-day range of the stock was $3.22 to $3.47. Sophiris Bio Inc (NASDAQ:SPHS) has a market capitalization of $52.81million.

Raleigh diagnostics company LipoScience, Inc. (NASDAQ:LPDX) terminated its relationship with Health Diagnostics Laboratory, Inc, one of its laboratory customers, after HDL began offering its own version of roughly the same test LipoScience Inc (NASDAQ:LPDX)manufactures. LipoScience Inc (NASDAQ:LPDX)’s stock on Mar 31, 2014 reported a increase of 5.28% to the closing price of $3.19. Its fifty two weeks range is $2.96 -$10.50. The total market capitalization recorded $48.45million. The overall volume in the last trading session was 105,983.00million shares. In its share capital, LPDX has 15.18million outstanding shares.

Drug developer Akebia Therapeutics and burn treatment maker MediWound Ltd (NASDAQ:MDWD) both went public Thursday as the tide of health care IPOs continued to rise. On Monday, shares of Mediwound Ltd (NASDAQ:MDWD) dropped -4.57% to close the day at $14.41.